Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B-Reference-Cited by-同舟云学术

Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B

Published:2019-11-25 Issue:1 Volume:85 Page:217-223
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Yuki Satoshi,Shinozaki Katsunori,Kashiwada Tomomi,Kusumoto Tetsuya,Iwatsuki Masaaki,Satake Hironaga,Kobayashi Kazuma,Esaki Taito,Nakashima Yuichiro,Kawanaka Hirofumi,Emi Yasunori,Komatsu Yoshito,Shimokawa Mototsugu,Makiyama Akitaka,Saeki Hiroshi,Oki Eiji^ORCID,Baba Hideo,Mori Masaki

Funder

Yakult Honsha

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03991-3.pdf

Reference21 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210

2. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5(2):189–190

3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72(1):37–41